COVID-19 Antibody Response by Vaccine Type and Lymphocyte Count in RMS Patients on Ponesimod: Results From Phase 2 Long-term Extension Study AC-058B202 (P12-3.003)

Wong, Janice; Hertoghs, Nina; Lemle, Alexandre; Linscheid, Philippe; Raghavan, Nandini; Singh, Amita; Sidorenko, Tatiana

doi:10.1212/wnl.0000000000202511

Neurology

2023

DOI: 10.1212/wnl.0000000000202511

|View full text |Cite

COVID-19 Antibody Response by Vaccine Type and Lymphocyte Count in RMS Patients on Ponesimod: Results From Phase 2 Long-term Extension Study AC-058B202 (P12-3.003)

Janice Wong

Nina Hertoghs

Alexandre Lemle

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis

Roberts¹

2023

EMJ Neurol

View full text Add to dashboard Cite

While people with multiple sclerosis (MS) are not more likely to contract COVID-19, the incidences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and COVID-19-related complications may be higher for people with MS who have comorbidities or who are taking certain disease modifying therapies (DMT). Robert Shin, Professor of Neurology at MedStar Georgetown University Hospital, Washington, D.C., USA, and Deborah Fuller, Department of Microbiology, University of Washington School of Medicine, and Associate Director of the Washington National Primate Research Center, Seattle, Washington, USA, first discussed why vaccinations against SARS-CoV-2 should be recommended to people with MS. They then discussed evidence that suggests that the antibody response following vaccination may be dampened in people taking some DMTs, especially those that deplete CD20+ B cells; however, T cell responses to vaccinations may also provide protection. There is also evidence that messenger RNA (mRNA) SARS-CoV-2 vaccines, as opposed to viral vector or recombinant protein subunit vaccines, and boosters may lead to a better antibody response. Vaccine responses vary between patients taking different sphinogosine-1-phosphate (S1P) receptor modulators, being low for fingolimod and high for next generation S1P receptor modulators. Overall, more studies of vaccine response and timing are needed to best update the guidelines for people with MS.

show abstract

The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis

Roberts¹

2023

EMJ Neurol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

COVID-19 Antibody Response by Vaccine Type and Lymphocyte Count in RMS Patients on Ponesimod: Results From Phase 2 Long-term Extension Study AC-058B202 (P12-3.003)

Cited by 1 publication

References 0 publications

The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis

The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis

Contact Info

Product

Resources

About